Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07482865

Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support

A prospective, multi-center, open label, randomized controlled, superiority trial to compare clinical outcomes between routine distal perfusion catheter (DPC) insertion versus provisional distal perfusion catheter (DPC) insertion in the occurrence of sign or symptom of acute limb ischemia in patients undergoing mechanical circulatory support (MCS) through femoral artery approach.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Gyeongsang National University Changwon Hospital, Changwon, South Korea

Loading trial locations.

About this study

Acute limb ischemia is a well-recognized vascular complication following peripheral mechanical circulatory support (MCS) including veno-arterial extracorporeal membrane oxygenation (VA-ECMO) or a percutaneous microaxial ventricular assist device (Impella) via femoral arterial cannulation, with reported incidence rates ranging up to 10-30% of patients. Distal perfusion catheter (DPC) has been introduced as a strategy to restore antegrade flow distal to the femoral arterial cannula, aiming to mitigate ischemic complications by augmenting perfusion through antegrade flow into the superficial femoral artery.

Current practice guidance from the Extracorporeal Life Support Organization (ELSO) supports the use of ipsilateral DPC placement at the time of peripheral VA-ECMO cannulation to reduce the risk of limb ischemia and recommends monitoring for adequate flow using Doppler or near-infrared spectroscopy (NIRS). However, these recommendations are predominantly based on observational studies and expert consensus, and do not stem from randomized controlled trial evidence. Current expert consensus and related guidelines describe that routine prophylactic DPC insertion should be considered in patients undergoing VA-ECMO as Class IIa (Level of evidence B) recommendation.

Several observational cohort studies have associated routine prophylactic DPC with reduced limb ischemia compared with no DPC placement, yet these are limited by confounding bias and variability in clinical practice patterns. Retrospective data suggested that delayed or rescue insertion after onset of limb ischemia may be less effective at preventing major ischemic sequelae than earlier DPC insertion strategies.

Given the absence of robust evidence from randomized controlled trial, it remains uncertain whether a strategy of routine prophylactic DPC insertion would be superior over a provisional DPC insertion guided by clinical monitoring in terms of limb ischemia reduction, limb-related morbidity, duration of MCS, and other clinical outcomes including in-hospital mortality.

In this regard, Routine versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support (PERFUSE-MCS) trial was designed to compare clinical outcomes between routine DPC insertion versus provisional DPC insertion in the occurrence of sign or symptom of acute limb ischemia in patients undergoing MCS through femoral artery approach.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 19 years old
  • Cardiogenic shock requiring mechanical circulatory support through femoral artery approach
  • Subject who can verbally confirm understandings of risks and benefits of receiving distal perfusion catheter insertion and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure.
  • Under the critically-ill clinical circumstance (unclear consciousness of patient), legally authorized representative can provide written informed consent prior to any study related procedure.

Exclusion criteria

  • Apparent symptoms and sign of acute limb ischemia immediately after mechanical circulatory support insertion
  • Significant coagulopathy precluding invasive procedure due to high risk of bleeding
  • Pregnant women, women with potential childbearing, or lactating women
  • Irreversible limb ischemia requiring interventional procedures or surgery at the time of MCS insertion
  • Previous history if femoral-femoral bypass grafting or femoral-popliteal bypass grafting
  • Previous history of limb amputation
  • Unwilling or unable to obtain informed consent from the participant or legally authorized representative

Treatment and study plan

Distal perfusion catheter insertion

Procedure

Distal perfusion catheter insertion under fluoroscopy or ultrasouond guidance in ipsilateral femoral artery to prevent limb ischemia.

Other names: DPC insertion

Primary outcomes

  1. Major limb ischemia requiring intervention

    Time frame: within 30 days from randomization

    Major limb ischemia requiring intervention

Secondary outcomes

  1. All-cause mortality

    Time frame: within 90 days from randomization

    Time to all-cause mortality

  2. Cardiovascular mortality

    Time frame: within 90 days from randomization

    Time to cardiovascular mortality

  3. Successful weaning of mechanical circulatory device

    Time frame: within 90 days from randomization

    Successful weaning of mechanical circulatory device

  4. Bleeding

    Time frame: within 90 days from randomization

    Bleeding defined by BARC type 2,3, or 5

  5. Systemic thromboembolism other than stroke during MCS

    Time frame: within 90 days from randomization

    Systemic thromboembolism other than stroke during MCS

  6. Cerebrovascular accidents

    Time frame: within 90 days from randomization

    Cerebrovascular accidents (ischemic stroke or hemorrhagic stroke)

  7. Rates of renal replacement therapy during index hospitalization

    Time frame: within 30 days from randomization

    Rates of renal replacement therapy during index hospitalization

  8. Duration of MCS during index hospitalization

    Time frame: within 30 days from randomization

    Duration of MCS during index hospitalization

  9. Duration of hospital stay during index hospitalization

    Time frame: within 30 days from randomization

    Duration of hospital stay during index hospitalization

  10. Duration of mechanical ventilation during index hospitalization

    Time frame: within 30 days from randomization

    Duration of mechanical ventilation during index hospitalization

Study contacts

Contact information is provided by the study sponsor or research team.

Jeong Hoon Yang, MD, PhD

CONTACT

[email protected]

82234102575

Joo Myung Lee, MD, MPH, PhD

CONTACT

[email protected]

82234102575

Sponsors and collaborators

Lead sponsor

Samsung Medical Center

Other

Collaborators

  • Eunpyeong St. Mary's Hospital
  • Gyeongsang National University Changwon Hospital
  • Korea University Anam Hospital
  • Kwandong University Intl. ST. Mary's Hospital
  • Samsung Changwon Hospital

Registry information

Acronym: PERFUSE-MCS

Important dates

Study start
2026
Primary completion
2030
Study completion
2030
First posted
Mar 19, 2026
Registry last updated
Mar 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.